Overview

Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis

Status:
Withdrawn
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate non inferiority of Eurofarma budesonide nasal spary x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.
Phase:
Phase 3
Details
Lead Sponsor:
Eurofarma Laboratorios S.A.
Treatments:
Budesonide